2007, Number S4
<< Back Next >>
Arch Cardiol Mex 2007; 77 (S4)
Atrial fibrillation: the relation between heart and brain
Plesiewicz I, Kuilenburg J, Gheorghe AMP
Language: English
References: 33
Page: 111-115
PDF size: 130.11 Kb.
Text Extraction
Introduction
According to the holistic view in medicine, the entire human organism is primary and the entire organism is greater than the sum of its parts; the parts are related in such a way that their functioning is conditioned by their relationship to each other. Where the atomist believes that any whole can be broken down or analyzed into its separate parts, the holist looks at things or systems in aggregate and argues that we can know more about them in considering them in their interrelationship as part of the whole (Fig. 1).
REFERENCES
Kannel WB, Wolf PA, Benjamin EJ, Levy D: Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82: 2N-9N.
Go AS, Hylek EM, Philips KA, Chang Y, Henault LE, Selby JV, Singer DE: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 2001; 285: 2370-2375.
Wattigney WA, Mensah GA, Croft JB: Increasing trends in hospitalization for atrial fibrillation in the United States., 1985 through 1998: implications for primary prevention. Circulation 2003; 108: 711-716.
Movahed M, Hashemzadeh M, Mazen JM: Diabetes mellitus is a strong, independent risk for atrial fibrillation in addition to other cardiovascular disease. Int J Cardiol 2005; 105: 315-318.
Fuster V, et al: Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. Circulation 2006; 114(7): 257-354.
Hart RG, Benavente O, McBride R: Antithrombotic therapy to prevent stroke in atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492-501.
Chang Yj, Ryu SJ, Lin SK: Carotid artery stenosis in ischemic stroke patients with nonvalvular atrial fibrillation. Cerebrovasc Dis 2002; 13: 16-20.
Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-126.
Libby P: Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
Libby P, Ridker P, Maseri A: Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
Boos CJ, Anderson RA, Lip GYH: Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006; 27: 136-149.
Patti G, Chello M, Candura D: Randomized trial of atorvastatin for reduction of Postoperative Atrial Fibrillation in patients undergoing cardiac surgery. Results of the ARMYDA-3. Circulation 2006; 114: 1455-1461.
Young-Xu Y, Jabbour S, Goldberg R: Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003; 92: 1379-1383.
Weng X, Cloutier G, Beaulieu R, Roederer GO: Influence of acute-phase proteins on erythrocyte aggregation. Am J Physiol 1996; 271: H2346-2352.
Devereux RB, Drayer JIM, Chien S: Whole blood viscosity as a determinant of cardiac hypertrophy in systemic hypertension. Am J Cardiol 1984; 54: 592-596.
Goldsmith HL, Turitto VT: Rheological aspects of thrombosis and haemostasis: Basic principles and applications. Thromb and Haemost 1986; 55: 415-435.
Koenig W, Ernst E: The possible role of hemorheology in atherothrombogenesis. Review Article. Atherosclerosis 1992; 94: 93-107.
Chien S, Usami S, Dellenback RJ, Gregersen MI: Blood viscosity: influence of erythrocyte aggregation. Science 1967; 157: 829-831.
Schmid-Schonbein H, Gaethgens P, Hirsch H: On the shear rate dependence of red cell aggregation in vitro. J Clin Invest 1968; 47: 1447-1454.
Task Force American Heart Association. From vulnerable plaque to vulnerable patient. Circulation 2003; 108: 1664-1698.
Lefebvre C, Deplanque D, Touze E: Prestroke dementia in patients with atrial fibrillation. Frequency and associated factors. J Neurol 2005; 252: 1504-1509.
De Leeuw FE, de Groot JC, Oudkerk M: Atrial fibrillation and the risk of cerebral white matter lesions. Neurology 2000; 54(9): 1795-1801.
EAFT Study Group. Silent brain infarction in nonrheumatic atrial fibrillation. European Atrial Fibrillation Trial. Neurology 1996; 46: 159-165.
Stanley T, Mackensen GB, Grocott H: The impact of postoperative atrial fibrillation on neurocognitive outcome after coronary artery bypass surgery. Anesth Analg 2002; 94: 290-295.
Grotta J, Ackerman R, Correja, Fallick G, Chang J: Whole blood viscosity parameters and cerebral blood flow. Stroke 1982; 13: 296-302.
Ackerman RH: Cerebral blood flow and neurological change in chronic heart failure. Stroke 2001; 32: 2462-4.
Black IW, Chesterman CN, Hopkins AP, Lee LC, Chong BH, Walsh WF: Hematologic correlates of left atrial spontaneous echo contrast and thromboembolism in nonvalvular atrial fibrillation. J Am Coll Cardiol 1993; 21: 451-457.
Sigel B, Machi J, Beitler JC, Justin JR: Red cell aggregation as a cause of blood-flow echogenicity. Radiology 1983; 148: 799-802.
Ito T, Suwa M, Nakamura T, Miyazaki S, Hirota Y, Kawamura K: Influence of Warfarin therapy on left atrial spontaneous echo contrast in nonvalvular atrial fibrillation. Am J Cardiol 1999; 84:857-9.
Bernick C, Katz R, Smith NL: Statins and cognitive function in the elderly: the Cardiovascular Health Study. Neurology 2005; 8: 1388-1394.
Hagens VE, Ranchor AV, van Sonderen E: Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol 2004; 43(2): 241-247.
Wyse DG, Waldo AL, DiMarco: A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347 (23):1825-1833.
Lozano HF, Conde CA, Lamas GA: Treatment and prevention of atrial fibrillation with non-antiarrhythmic pharmacologic therapy. Heart Rhythm 2005; 2(9): 1000-1007. Review.
Full text